Prudential Financial Inc Agenus Inc Transaction History

Prudential Financial Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.53 - $0.93 $53,742 - $94,302	101,400 Added 414.98%	125,835 $72,000
Q4 2023 Feb 13, 2024	BUY	$0.63 - $1.14 $1,568 - $2,838	2,490 Added 11.35%	24,435 $20,000
Q2 2023 Aug 11, 2023	BUY	$1.31 - $2.04 $3,772 - $5,875	2,880 Added 15.11%	21,945 $35,000
Q1 2023 May 12, 2023	SELL	$1.45 - $2.95 $460,665 - $937,215	-317,700 Reduced 94.34%	19,065 $28,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.25 $2.12 Million - $3.42 Million	-1,051,070 Reduced 75.73%	336,765 $0
Q3 2022 Nov 04, 2022	BUY	$1.96 - $3.14 $2.69 Million - $4.3 Million	1,370,145 Added 7745.31%	1,387,835 $2.85 Million
Q2 2022 Aug 15, 2022	BUY	$1.3 - $2.64 $2,964 - $6,019	2,280 Added 14.8%	17,690 $34,000
Q4 2021 Feb 14, 2022	SELL	$2.92 - $5.74 $1,124 - $2,209	-385 Reduced 2.44%	15,410 $50,000
Q3 2021 Nov 15, 2021	BUY	$4.98 - $6.63 $9,013 - $12,000	1,810 Added 12.94%	15,795 $83,000
Q2 2021 Aug 16, 2021	BUY	$2.56 - $5.49 $7,193 - $15,426	2,810 Added 25.15%	13,985 $77,000
Q1 2021 May 12, 2021	SELL	$2.69 - $5.25 $807 - $1,575	-300 Reduced 2.61%	11,175 $30,000
Q4 2020 Feb 16, 2021	BUY	$3.17 - $4.49 $2,932 - $4,153	925 Added 8.77%	11,475 $36,000
Q3 2020 Nov 16, 2020	BUY	$2.98 - $5.2 $31,439 - $54,860	10,550 New	10,550 $42,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.